Insmed (INSM) Q1 2026 earnings review
BRINSUPRI Hyper-Growth Transforms the Financial Profile
Insmed is undergoing a massive financial inflection point. Q1 total revenue surged 230% YoY to $306.0M, driven entirely by the explosive launch of BRINSUPRI, which generated $207.9M in its second full quarter on the market. This top-line hockey stick is finally creating operating leverage: Net Loss narrowed substantially to $163.6M (from $256.6M a year ago), even as operating expenses climbed to support the launch. ARIKAYCE delivered modest 6% global growth, but the underlying US business contracted. Management reiterated aggressive 2026 guidance, including at least $1B for BRINSUPRI, and confidently projected cash flow positivity in 2027.
🐂 Bull Case
BRINSUPRI achieved $207.9M in Q1, accelerating 44% sequentially. With over 5,000 prescribers and a ~90% payor approval rate, the drug is tracking to exceed $1 billion in 2026 revenue, an achievement reached by only a handful of launches in pharmaceutical history.
The rapid revenue scale-up is outpacing expense growth. With $1.2 billion in cash on hand, management is fully capitalized to execute its pipeline and expects to reach cash flow positivity in 2027 without further dilution.
🐻 Bear Case
ARIKAYCE U.S. revenues declined 2% YoY to $62.9M. While international markets offset this with 23% growth, the legacy U.S. refractory MAC market appears saturated pending a label expansion.
Management continues to pause ex-U.S. BRINSUPRI commercial launches (despite U.K. approval in February) due to evolving U.S. pricing and tariff policies, isolating near-term growth to the American market.
⚖️ Verdict: 🟢
Bullish. The sheer scale and speed of the BRINSUPRI launch fundamentally derisks Insmed's balance sheet. While the U.S. ARIKAYCE stall is a point of monitoring, the massive revenue influx and positive ENCORE trial data overshadow the legacy concerns.
Key Themes
BRINSUPRI Mix Shift and Margin Expansion
Accelerating. BRINSUPRI is quickly becoming the core of Insmed's business, representing 68% of total Q1 revenues ($207.9M vs ARIKAYCE's $98.1M). Because BRINSUPRI is a small-molecule oral tablet, it carries significantly lower manufacturing costs than liposomal ARIKAYCE. This product mix shift drove a massive improvement in profitability profile: Cost of product revenues fell to just 15.5% of total sales in Q1 2026, down from 22.9% a year ago.
U.S. ARIKAYCE Revenue Decline
Reversing. A notable red flag emerged as ARIKAYCE U.S. revenues dropped 2% YoY to $62.9M. This directly contradicts the narrative of a steadily growing asset and suggests the U.S. refractory MAC market (an estimated 30,000 patients) may be reaching a ceiling. Total ARIKAYCE growth of 6% was salvaged entirely by a 23% surge in international markets ($35.2M).
ENCORE Trial Success Unlocks Massive TAM
Accelerating. Insmed reported that the Phase 3b ENCORE study for ARIKAYCE met its primary and all multiplicity-controlled secondary endpoints. This is a massive de-risking event. An sNDA filing is planned for H2 2026 to expand the label from refractory MAC lung disease to all MAC patients, which management estimates will expand the addressable market by approximately 200,000 additional patients globally.
Prescribing Depth Must Improve
Stable. While Insmed has successfully onboarded over 5,000 prescribers for BRINSUPRI since launch, their own data indicates that only ~20% of prescribers have written scripts for 5 or more patients. This implies that up to 80% of the prescriber base is still in a 'trial phase' (writing 1-4 scripts). Achieving the aggressive $1B+ guidance will require turning these trial prescribers into volume prescribers.
TPIP Program Advancing to Pivotal Trials
Accelerating. The clinical pipeline continues to progress with TPIP (treprostinil palmitil inhalation powder). Following an Orphan Drug Designation in January 2026, Insmed initiated the Phase 3 PALM-PAH study in April 2026. This novel prostanoid uses a dry powder formulation designed to provide slow release, limiting airway side effects while providing high, consistent drug levels—a specific technological innovation that could disrupt existing PAH therapies.
Macro Pressures Delaying Ex-U.S. BRINSUPRI Launch
Stable. Despite receiving U.K. MHRA approval for BRINSUPRI in February 2026, management explicitly stated they are holding back on international commercial launches to 'evaluate the potential effect of evolving U.S. policies.' This likely refers to MFN (Most Favored Nation) pricing rules or tariff risks. Consequently, ex-U.S. revenue contribution for BRINSUPRI will be near zero in 2026, putting the entire burden of the $1B guidance on the U.S. market.
Other KPIs
Accelerating. R&D increased 37% YoY to $209.5M, driven by manufacturing costs and Phase 3 trial initiations (PALM-PAH). SG&A jumped 68% YoY to $247.3M, directly linked to the commercial ramp of BRINSUPRI. However, because revenue grew 230%, the operating expense ratio as a percentage of sales dropped dramatically, signaling the beginning of true operating leverage.
Stable. The cash position is slightly down from year-end 2025 levels, reflecting the planned burn to fund the commercial launch and broad clinical pipeline. Management reiterated this runway is sufficient to reach cash flow positivity in 2027 without raising additional equity.
Guidance
Accelerating. Management reiterated this highly aggressive target. Achieving $1B after posting $207.9M in Q1 requires BRINSUPRI to average roughly $264M per quarter for the remainder of the year. Given the 44% QoQ growth rate witnessed in Q1, the company is currently pacing well ahead of the required run rate.
Accelerating. The midpoint of $460M implies ~6% YoY growth from FY25's $433.8M. However, with Q1 delivering $98.1M, ARIKAYCE will need to average over $120M per quarter in Q2-Q4 to hit the midpoint. Given the U.S. market contracted by 2% in Q1, achieving this guidance heavily relies on accelerating international sales.
Stable. The company is actively controlling early-stage spend to ensure capital is directed toward the commercialization of BRINSUPRI and the late-stage Phase 3 trials of TPIP.
Key Questions
Path to ARIKAYCE Guidance
With U.S. ARIKAYCE revenues contracting 2% YoY in Q1, what are the specific commercial levers you intend to pull to achieve the $450-$470M full-year guidance, which implies a required acceleration in quarterly run rates for the rest of the year?
Prescribing Depth for BRINSUPRI
You have done an excellent job capturing over 5,000 prescribers, but roughly 80% have written scripts for fewer than 5 patients. What are the primary friction points preventing these 'trial' prescribers from adopting BRINSUPRI across their broader eligible patient panels?
Ex-U.S. Launch Strategy and U.S. Policy
Can you provide more specifics on the 'evolving U.S. policies' that are pausing the international rollout of BRINSUPRI? What specific policy clarity do you need before initiating the U.K. launch following your recent MHRA approval?